{
  "main_header": {
    "sid": 1002639,
    "name": "Kwality Pharma",
    "stock_name": "Kwality Pharma",
    "full_name": "Kwality Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/kwality-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "817.95",
    "chg": 40.95,
    "chgp": "5.27%",
    "dir": 1,
    "prev_price": "777.00",
    "mcapval": "848.72 Cr",
    "mcap": "Micro Cap",
    "scripcode": 539997,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE552U01010",
    "curr_date": "Apr 11, 12:53 PM",
    "curr_time": "01:30 AM",
    "bse_nse_vol": "2.69 k",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/kwality-pharma-1002639-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Kwality Pharmaceuticals Adjusts Valuation Grade Amid Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kwality-pharmaceuticals-valuation-grade-changes-from-fair-to-expensive-amid-price-increase-1656142",
        "imagepath": "",
        "date": "2025-04-01 08:00:39",
        "description": "Kwality Pharmaceuticals has recently undergone a valuation adjustment, reflecting its current standing in the pharmaceuticals and drugs sector. The company's price-to-earnings ratio stands at 26.31, while its price-to-book value is recorded at 3.79. Other key metrics include an EV to EBIT ratio of 17.74 and an EV to EBITDA ratio of 13.43, indicating its operational efficiency. The company's return on capital employed (ROCE) is at 16.61%, and return on equity (ROE) is 14.07%, showcasing its profitability.\n\nIn comparison to its peers, Kwality Pharmaceuticals maintains a competitive position, with its valuation metrics aligning closely with those of other companies in the industry. For instance, Shree Ganesh Rem and Fermenta Biotec also exhibit elevated valuation metrics, while companies like Kopran and Anuh Pharma present more attractive valuations. Notably, Kwality's stock performance has outpaced the Sensex..."
      },
      {
        "title": "Kwality Pharmaceuticals Reports Strong Q2 Results with Improved Profitability Metrics",
        "link": "https://www.marketsmojo.com/news/result-analysis/kwality-pharmaceuticals-reports-q3-fy24-25-operating-profit-to-interest-ratio-of-7-95-times-580493",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/1/KwalityPharmace_quaterlyResult_318551.png",
        "date": "2025-01-31 22:02:38",
        "description": "Kwality Pharmaceuticals has announced its financial results for the quarter ending December 2024, revealing significant improvements. The company's operating profit to interest ratio has reached 7.95 times, while profit after tax for the half-year is Rs 17.00 crore, reflecting a year-on-year growth of 22.04%. Earnings per share have also increased to Rs 8.22."
      }
    ],
    "total": 49,
    "sid": "1002639",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/kwality-pharmaceuticals-1002639"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "09-Apr-2025",
      "details": "Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulations 2018 for quarter ended 31-03-2025.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "26-Mar-2025",
      "details": "Closure of Trading Window.",
      "source": "BSE"
    },
    {
      "caption": "Kwality Pharmaceutical Limited Receives Product Registration Of Cyclophosphamide 1Gm In Mexico",
      "datetime": "14-Feb-2025",
      "details": "Kwality Pharmaceuticals Limited receives product registrartion of Cyclophosphamide 1gm in Mexico",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Kwality Pharmaceuticals Ltd has declared <strong>6%</strong> dividend, ex-date: 05 Jan 17",
          "dt": "2017-01-05",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Kwality Pharmaceuticals Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 11 Oct 17",
          "dt": "2017-10-11",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Kwality Pharmaceuticals Adjusts Valuation Grade Amid Competitive Market Landscape

2025-04-01 08:00:39

Kwality Pharmaceuticals has recently undergone a valuation adjustment, reflecting its current standing in the pharmaceuticals and drugs sector. The company's price-to-earnings ratio stands at 26.31, while its price-to-book value is recorded at 3.79. Other key metrics include an EV to EBIT ratio of 17.74 and an EV to EBITDA ratio of 13.43, indicating its operational efficiency. The company's return on capital employed (ROCE) is at 16.61%, and return on equity (ROE) is 14.07%, showcasing its profitability. In comparison to its peers, Kwality Pharmaceuticals maintains a competitive position, with its valuation metrics aligning closely with those of other companies in the industry. For instance, Shree Ganesh Rem and Fermenta Biotec also exhibit elevated valuation metrics, while companies like Kopran and Anuh Pharma present more attractive valuations. Notably, Kwality's stock performance has outpaced the Sensex...

Read More

Kwality Pharmaceuticals Reports Strong Q2 Results with Improved Profitability Metrics

2025-01-31 22:02:38

Kwality Pharmaceuticals has announced its financial results for the quarter ending December 2024, revealing significant improvements. The company's operating profit to interest ratio has reached 7.95 times, while profit after tax for the half-year is Rs 17.00 crore, reflecting a year-on-year growth of 22.04%. Earnings per share have also increased to Rs 8.22.

Read More

View All News